NOT FOR DISTRIBUTION
Header cover image

Yantai Dongcheng Pharmaceutical GroupLtd

Market Cap

CN¥15.3b

Last Updated

2021/05/09 09:31 UTC

Data Sources

Company Financials +

Executive Summary

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical API products in China. More Details


Snowflake Analysis

Solid track record with excellent balance sheet.


Similar Companies

Share Price & News

How has Yantai Dongcheng Pharmaceutical GroupLtd's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 002675 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 002675's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-7.7%

2675

-7.9%

CN Biotechs

-2.0%

CN Market


1 Year Return

13.2%

2675

47.9%

CN Biotechs

22.3%

CN Market

Return vs Industry: 002675 underperformed the CN Biotechs industry which returned 47.9% over the past year.

Return vs Market: 002675 underperformed the CN Market which returned 22.3% over the past year.


Shareholder returns

2675IndustryMarket
7 Day-7.7%-7.9%-2.0%
30 Day-6.1%3.9%-1.4%
90 Day-6.3%-2.0%-3.6%
1 Year14.8%13.2%48.2%47.9%24.1%22.3%
3 Year57.5%54.4%81.6%79.1%26.7%20.6%
5 Yearn/a83.2%80.0%37.3%28.1%

Long-Term Price Volatility Vs. Market

How volatile is Yantai Dongcheng Pharmaceutical GroupLtd's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Yantai Dongcheng Pharmaceutical GroupLtd undervalued compared to its fair value and its price relative to the market?

37.24x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 002675 (CN¥19.07) is trading above our estimate of fair value (CN¥4.47)

Significantly Below Fair Value: 002675 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 002675 is good value based on its PE Ratio (37.2x) compared to the CN Biotechs industry average (51.9x).

PE vs Market: 002675 is poor value based on its PE Ratio (37.2x) compared to the CN market (30.2x).


Price to Earnings Growth Ratio

PEG Ratio: 002675 is poor value based on its PEG Ratio (1.5x)


Price to Book Ratio

PB vs Industry: 002675 is good value based on its PB Ratio (3.4x) compared to the CN Biotechs industry average (5.1x).


Future Growth

How is Yantai Dongcheng Pharmaceutical GroupLtd forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

24.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 002675's forecast earnings growth (24.6% per year) is above the savings rate (3.3%).

Earnings vs Market: 002675's earnings (24.6% per year) are forecast to grow faster than the CN market (21.2% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 002675's revenue (14% per year) is forecast to grow slower than the CN market (16.9% per year).

High Growth Revenue: 002675's revenue (14% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 002675's Return on Equity is forecast to be low in 3 years time (14%).


Past Performance

How has Yantai Dongcheng Pharmaceutical GroupLtd performed over the past 5 years?

22.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 002675 has high quality earnings.

Growing Profit Margin: 002675's current net profit margins (11.4%) are higher than last year (5.2%).


Past Earnings Growth Analysis

Earnings Trend: 002675's earnings have grown significantly by 22% per year over the past 5 years.

Accelerating Growth: 002675's earnings growth over the past year (150.4%) exceeds its 5-year average (22% per year).

Earnings vs Industry: 002675 earnings growth over the past year (150.4%) exceeded the Biotechs industry 34.9%.


Return on Equity

High ROE: 002675's Return on Equity (10.3%) is considered low.


Financial Health

How is Yantai Dongcheng Pharmaceutical GroupLtd's financial position?


Financial Position Analysis

Short Term Liabilities: 002675's short term assets (CN¥3.0B) exceed its short term liabilities (CN¥2.0B).

Long Term Liabilities: 002675's short term assets (CN¥3.0B) exceed its long term liabilities (CN¥536.9M).


Debt to Equity History and Analysis

Debt Level: 002675's debt to equity ratio (19.2%) is considered satisfactory.

Reducing Debt: 002675's debt to equity ratio has increased from 14% to 19.2% over the past 5 years.

Debt Coverage: 002675's debt is well covered by operating cash flow (63.7%).

Interest Coverage: 002675's interest payments on its debt are well covered by EBIT (15.6x coverage).


Balance Sheet


Dividend

What is Yantai Dongcheng Pharmaceutical GroupLtd current dividend yield, its reliability and sustainability?

1.31%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 002675's dividend (1.31%) is higher than the bottom 25% of dividend payers in the CN market (0.47%).

High Dividend: 002675's dividend (1.31%) is low compared to the top 25% of dividend payers in the CN market (1.87%).


Stability and Growth of Payments

Stable Dividend: 002675 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 002675's dividend payments have increased, but the company has only paid a dividend for 8 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (48.8%), 002675's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average board tenure


CEO

Yantai Dongcheng Pharmaceutical GroupLtd has no CEO, or we have no data on them.


Board Members

Experienced Board: 002675's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
  • Ticker: 2675
  • Exchange: SZSE
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥15.298b
  • Shares outstanding: 802.21m
  • Website: https://www.dcb-group.com

Number of Employees


Location

  • Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
  • No.7 ChangBaiShan Road
  • Yantai Development Zone
  • Yantai
  • Shandong Province
  • 264006
  • China

Listings


Biography

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical API products in China. It offers heparin, chondroitin sulphate, and glucos...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/09 09:31
End of Day Share Price2021/05/07 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.